CytomX Therapeutics Announces the Planned Retirement of Chief Scientific Officer, W. Michael …,

Dr. Belvin joined CytomX in 2018, bringing close to 20 years of industry experience in oncology research and drug discovery to the company. Prior to …, Dr. Belvin joined CytomX in 2018, bringing close to 20 years of industry experience in oncology research and drug discovery to the company. Prior to …, Read More